







































Adverse effects of heavy cannabis use: even plants
can harm the brain
Lucia Sidelia, Giulia Trottaa, Edoardo Spinazzolaa,b, Caterina La Casciac, Marta Di Fortid,e,f,*
1. Introduction
The spread of laws legalising cannabis for medicinal or
recreational use has been accompanied by more relaxed
attitudes towards cannabis. Data from the United States
show that in states that have legalised cannabis, prevalence
of daily, weekly, and monthly cannabis use was 11.3%,
18.3%, and 25.0% respectively, whereas in countries where it
is still illegal, it was lower (7.4%, 11.6%, and 16.8%
respectively).46 Evidence indicates a trend of increase among
adolescents,58 a particular vulnerable category for the initi-
ation of substance use.114 In parallel, we have seen the
concentration of THC (D-9-tetrahydrocannabinol) in the
cannabis sold both in the United States and in Europe rising
and those types of cannabis with high THC,35 and a corre-
sponding decrease of cannabidiol (CBD) content,17,35,95
becoming more widely available. Most commonly, cannabis
is used for its enjoyable effects, the “high” feeling.69 In
addition, in those countries where its use has been legalised,
many people smoke cannabis for medical use, anxiety,
depression, and pain relief,71 with those suffering from
chronic pain being at higher risk of developing cannabis use
disorder (CUD).57
This review aims to challenge the widespread view that
cannabis being a “plant” does not carry adverse effects, and
review the evidence concerning the effects of cannabis use on
mental health and cognition.
2. Understanding cannabis
The plant Cannabis sativa contains more than 100 different
psychoactive ingredients,33,53,74 but the most widely studied are
THC (D-9-tetrahydrocannabinol) and CBD (cannabidiol),36,74,84
synthesised from the same precursor, cannabigerol. Therefore,
types of cannabis with high concentrations of THC produce low
CBD and vice versa.23
THC is a partial agonist at both the cannabinoid receptors (CB)
CB2 R and CB1 R, the latter highly abundant in the brain.
64, 83, 97
THC is responsible for most of the enjoyable and adverse effects
that commonly arise after acute and regular cannabis use.8,24,116
Conversely, CBD is a negative allostericmodulator at the CB1R,
76
whose effects are distinct and, in many cases, opposite of those
observedwith THC. CBDdoes not induce euphoria butmay exert
anxiolytic, antiepileptic, anti-inflammatory, and analgesic prop-
erties Figure 1.9,10,22,91,99,100,108
3. Cannabis intoxication and dependence
3.1. Acute adverse effects
Cannabis use can lead to intoxication, defined as a series of
“clinically significant problematic behavioural or psychological
changes (eg, impaired motor coordination, euphoria, anxiety,
sensation of slowed time, impaired judgment, and social withdrawal)
that develop during, or shortly after, cannabis use.”2 The experience
of feeling “high” after cannabis use is variable and subjective,48
depending on the dose, the environment, and previous experience
and expectations of the drug user.101 The most common acute
adverse effects are panic attacks and other forms of anxiety, mostly
reported by naive users.50,51 Because cannabis impairs psycho-
motor skills, reaction time, and motor coordination, its use leads to
increased risk ofmotor vehicle accidents.6,98Current cannabis users
have higher rates of hospitalization for injury from all causes than
former cannabis users or nonusers.41
3.2. Cannabis use disorders
DSM-5 CUDs is now a single diagnostic entity including abuse
and dependence3; it is prevalent (2.54% 12-month prevalence
among U.S. adults), associated with comorbidity and disability,
and largely untreated.56 Moreover, CUD often presents
comorbidly with psychotic disorders.59 Preclinical studies sup-
port the evidence that exposure to THC leads to depen-
dence.1,16,19 Cannabis can induce tolerance in humans60,65
and dependence.16 Because cannabis is eliminated slowly from
the body, withdrawal symptoms are generally mild. Nevertheless,
discontinuation of long-term frequent cannabis use can induce
anger, decreased appetite, irritability, nervousness, restlessness,
and sleep difficulties,13,79 suggesting that the alleviation of
abstinence symptoms contributes to the maintenance of daily
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cannabis use.52 Recent evidence, from the Netherlands, has
shown an association between changes over time in average
THC content in the type of cannabis available and rates of
admission to specialist cannabis treatment units.37
4. Cannabis and psychosis
4.1. Epidemiological evidence
Cross-sectional and prospective studies demonstrate a causal link
between cannabis use and psychotic disorder, with greater risk for
cannabis users, compared to nonusers.73,85,88,89 The most recent
meta-analysis reported a pooled odds ratio (OR) 5 3.90 (95%
confidence interval [CI] 2.84-5.34) and shows a dose–response
association between cannabis use and psychosis outcomes.82
Furthermore, findings from general population studies indicate, even
after statistical adjustment for other known psychosis risk factors,
a strong association between cannabis use and psychotic symp-
toms, and especially paranoia, beyond the clinical disorder.34,92,95,102
4.2. Harmful patterns of cannabis use
Data from South London showed that use of high-potency
cannabis (skunk-type average THC% 5 14%), compared to
never use, was associated with a 3-fold risk (OR5 2.92, 95% CI
1.52-3.45), which increased to 5-fold when the use was daily (OR
5 5.4, 95% CI 2.81-11.31), of developing psychotic disorders;
hash-like cannabis use carried no additional risk compared to
never use—likely because of ratio of THC: CBD5 1 ratio in most
of the London hash available at the time of the study.28,29
Consistently, survey data from general population samples
suggest that use of cannabis with high CBD content is associated
with fewer psychotic experiences.10,87 Morgan and Curran87
showed that healthy volunteers with hair traces of THC and
cannabidiol reported less schizophrenia-like symptoms than
those with only THC in their hair traces of THC.87
More recently, data from the EUGEI study, a large multicentre
European collaboration,40 confirmed that those who use daily
types of cannabis with THC content 5.10% are 5 times (OR5
4.8; 95% CI 2.5-6.3) more likely to suffer from psychotic disorder
than never users30; a risk that was greater OR 5 9.43 (95% CI
6.2-19.6) in Amsterdamwhere popular types of cannabis such as
Nederhasj andNederwiet have THCcontents that can reach 67%
and 22%, respectively.30,90 Moreover, first episode psychosis
patients (FEP), who used high-potency cannabis daily experi-
enced, at their illness onset, more prominent positive symptoms
(eg, delusions and hallucinations) and, in particular, paranoia.96
4.3. Cannabis use and age of onset of psychotic disorders
A meta-analysis by Large et al.77 reported that subjects who used
cannabis experienced, on average, their illnessonset 3 years earlier
compared to never users, a significantly higher effect than for use of
other drugs including alcohol. Another study showed that if
subjects had used high-potency cannabis daily, their illness onset
was, on average, 6 years earlier31 compared to never users.
4.4. Heavy cannabis use and rates of psychotic disorders
Boydell et al.11 claimed that cannabis consumption could impact
on the incidence of schizophrenia in those areas where the
prevalence of cannabis use is high. The first, clear evidence of the
impact of cannabis use on rates of psychotic disorder comes
from the EUGEI study. Across 11 European sites, the incident
rates for psychotic disorder—adjusted for age, sex, and
ethnicity—were positively correlated with the prevalence of use
of high-potency cannabis (r 5 0.7; P 5 0.0286) and, in-
dependently, with the prevalence of daily use (r 5 0.8; P 5
0.0109) among the controls representative of the local popula-
tions.30 These findings suggest that where daily cannabis use and
use of high-potency cannabis is prevalent in the general
population, there are more new cases of psychotic disorders.
Figure 1. This diagram graphically illustrated first, the differential and in fact opposite psychiatric and cognitive effects of THC and of CBD, and second, how both
compounds derive from the same precursor. Therefore if, for instance, aCannabis sativa plant is genetically driven to the production of high quantity of THC, it will
only be capable to synthesise small quantities of CBD.10
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Indeed, the study shows that 12% of patients with FEP across
Europe can be attributed to high-potency cannabis use, rising to
30% in London and 50% in Amsterdam.30 If high-potency
cannabis were no longer available, incidence in London would
drop from 46 3 100,000 to 32 3 100,000 person-years, even
after taking into account age, sex, and migration. Further
independent evidence comes from Portugal that has registered
a steady increase in the rate of hospital admissions for psychotic
disorders with comorbid CUD.45 Similar data were reported in
Denmark.59 Both countries have seen a rise in the potency of
available cannabis over the same period.35,111
4.5. Reverse causality and self-medication hypotheses
The self-medication hypothesis suggests that patients with
psychotic disorders use cannabis to seek relief from their
symptoms.4,43,106 The Christchurch Health & Development birth
cohort study showed that although cannabis use was associated
with increasing psychotic symptoms, the experience of psychotic
symptoms inhibits rather than encourages subsequent cannabis
use.25,26 Moreover, findings from the Dunedin birth cohort
indicated a specific temporal link between cannabis use and
onset of psychosis outcomes. Cannabis use at 15 years of age
was associated with a 4-fold increase in risk for schizophreniform
psychosis at 26 years of age (OR 5 4.50, 95% CI 1.11-18.21),
compared to never use. This association remained present (OR5
3.12; 95% CI 0.73-13.29) after excluding those participants who
at 11 years of age had reported psychotic symptoms, although
failed to reach significance because of reduced power.5
More recently, Mendelian randomization investigated the re-
lationship between cannabis use and randomly assorted genetic
variants that are associated with psychosis, which were used as
proxy for psychosis itself. Mendelian randomization studies have
suggested that cannabis use initiation is partly explained by
common genetic variants associated with risk of schizophrenia,
thus proposing a direction of causality from schizophrenia genes to
cannabis use (ie, reverse causality) rather than from cannabis use
to schizophrenia and other psychosis.39,93,115By contrast, findings
Table 1
Summary of meta-analyses reporting adverse effects associated with cannabis use.




66,816 individuals from 10 studies Random-effects meta-analysis on risk
of psychosis
High levels of cannabis use increase
the risk of psychotic outcomes with
a dose–response relationship
OR 5 3.9, 95% CI [2.84-5.34]
Large
et al.77
8167 substance using patients from
83 studies
Random-effects meta-analysis on age
at onset of psychosis
Relationship between cannabis use
and earlier onset of psychotic illness




16,565 individuals from 24 studies Random-effects meta-analysis on
clinical outcomes of psychosis
Continued cannabis use after onset of
psychosis predicts adverse outcome
than for nonusers




2391 individuals from 6 studies Random-effects meta-analysis Association between cannabis use
and both the exacerbation of manic
symptoms in those with previously
diagnosed bipolar disorder and new-
onset manic symptoms




22,317 individuals from 11 studies Random-effects meta-analysis Cannabis consumption in
adolescence is associated with
increased risk of developing
depression in young adulthood
OR 5 1.37, 95% CI [1.16-1.62]
Lev-Ran
et al.78
76,058 individuals from 14 studies Random-effects meta-analysis Heavy cannabis use may be
associated with an increased risk for
developing depressive disorders




22,317 individuals from 11 studies Random-effects meta-analysis No evidence of an association with
anxiety
OR 5 1.18, 95% CI [0.84-1.67]
Twomey
et al.113
58,538 individuals from 10 studies Random-effects meta-analysis Cannabis use is no more than a minor
risk factor for the development of
elevated anxiety symptoms in the
general population




623 cannabis users and 409 minimal
or non-cannabis users from 11
studies
Fixed-effects meta-analysis There might be decrements in the
ability to learn and remember new
information in chronic users, whereas
other cognitive abilities are unaffected
Learning ES 5 20.21, 99% CI
[20.39 to 0.02]
Forgetting/retrieval ES 5 20.27,
99% CI [20.49 to 20.04]
Schreiner
et al.107
1010 current or former cannabis
users and 837 controls with no or
limited cannabis use from 33 studies
Random-effects meta-analysis A small negative residual effect of
cannabis use on overall cognitive
performance, no evidence of lasting
residual effect
Overall cognitive performance ES 5
20.29, 95% CI [20.46 to 20.12]
Lasting residual effect ES 5 20.12,
95% CI [20.32 to 0.07]
This table illustrates the findings from meta-analyses that report an association between several mental health outcomes, cognition, and cannabis use.
CI, confidence interval; ES, effect size; OR, odds ratio.
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from the EUGEI study showed that (1) genetic summary score for
schizophrenia (polygenic risk score [PRS]) did not predict the
propensity to initiate cannabis use, (2) how frequently someone
uses it, and (3) the potency of the cannabis used. On the contrary,
heavy cannabis use increased the risk for psychotic disorders
independent of the individual’s schizophrenia PRS. For instance,
daily users of high-potency cannabis (THC5.10%) had a 5-fold
increase (OR 5 5.4; 95% CI 3.21-10.63) in their risk for psychotic
disorders, even after controlling for the schizophrenia PRS.32
4.6. Course and outcome of psychosis
A meta-analysis indicates that patients with a psychotic disorder
who continue to use cannabis after their illness onset experience
a worse clinical and functional outcome than those who stop.103
Data from a 2-year follow-up study showed that FEP who used
high-potency cannabis daily over the follow-up period were 3
times more likely to relapse (OR 5 3.28; 95% CI 1.22-9.18),
experienced more relapses (incidence rate ratio 1.77; 95% CI
0.96-3.25), and received more intense psychiatric care (OR 3.16;
95% CI 1.26-8.09), compared to those who stopped.18,104,105
Some evidence begin to suggest that individuals at ultra-high
risk for psychosis have higher rates of CUDs14 and, conversely,
patients with CUDs are more likely to transition to psychosis.72
4.7. Self-reported measures of cannabis use
All the above epidemiological studies rely on self-reported
current and/or lifetime information on cannabis use, not
validated by biological measures (eg, urine, blood, and hair
samples). This is often considered a limitation. Nevertheless,
although biological measures can provide valid and reliable
measures of current use, they cannot provide data on use over
time. Indeed, studies that analysed both self-reported in-
formation and laboratory data indicated that cannabis users
are reliable in reporting how frequently they use and the type
they used.21,36
4.8. Human experimental studies
Administration of cannabis and THC has shown to pre-
cipitate, with a dose–response relationship, the onset of
transient positive psychotic symptoms (eg, ideas of refer-
ence, paranoid delusions, hallucinations, depersonalization,
or derealization) and, to a less extent, negative symptoms (eg,
blunted affect) in healthy volunteers and to temporary
exacerbated psychotic symptoms in schizophrenia
patients.88,110 Furthermore, in healthy volunteers, adminis-
tration of CBD before the THC was found to ameliorate the
psychotogenic effects of THC.88,110
Table 2
Summary of the mental health and cognitive acute and persistent adverse effects associated with cannabis use.
Adverse effects Acute Persistent Pattern of cannabis use Vulnerable individuals
Onset of psychotic symptoms 111 111 1. Dose–response relationship (% THC)
2. CBD ameliorates THC effects
1. Family history of psychosis
2. High polygenic risk score for schizophrenia
3. Adolescents (age at first use 5 ,15 y)
Worsening of psychotic symptoms 111 111 1. Daily use of high-potency cannabis NAD
Onset of mania 112 112 1. Dose–response relationship with frequency of
use
NAD
Worsening of manic symptoms 112 112 1. Cannabis use disorder NAD
Depression 122 122 1. Dose–response relationship with frequency of
use
NAD
Anxiety 112 122 1. Dose–response relationship with frequency of
use
NAD
Suicidal ideation 122 122 NAD Adolescents (age at first use 5 ,15 y)
Dependence (CUD) NA 111 1. Dose–response relationship with THC content
(high-potency cannabis and daily use)
2. CBD ameliorates THC effects
NAD
Withdrawal symptoms NA 111 Long-term frequent use NAD
Psychomotor skills, reaction time, and motor
coordination
111 NAD 1. Dose–response relationship (% THC) Cannabis-naive individuals
Verbal learning and memory 111 122 1. Dose–response relationship (% THC)
2. CBD ameliorates THC effects
Working memory 112 122 1. Dose–response relationship (% THC)
2. CBD ameliorates THC effects
Spatial working memory 112 12 1. Dose–response relationship (% THC) Adolescents
Attention 111 112 1. Dose–response relationship (% THC)
2. CBD ameliorates THC effects
Adolescents
Executive function domains 112 122 NAD Adolescents
111, strong consistent evidence;112, modest evidence;122, weak or inconsistent evidence; CBD, cannabidiol; CUD, cannabis use disorder; NAD, not available data and/or not investigated; NA, not applicable; THC,
delta 9-tetrahydrocannabinol.
This table lists (1) the acute (2) and/or persistent effects that have been reported after cannabis use and the strength of the related evidence, (3) the patterns of cannabis use mostly associated with each adverse effects, and (4)
the individuals reported to be the most vulnerable to experience them.
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4.9. Vulnerable groups
The Dunedin study was the first to indicate adolescents as
a group particularly vulnerable to the psychotogenic effect of
cannabis use.5 Since then, other studies have reported an
association between early cannabis initiation and greater risk for
psychosis.15 It remains unclear if this association reflects (1)
a longer duration of exposure (eg, earlier start, longer use) or (2)
the vulnerability of a developing brain.88, 117
Subjects with a family history of psychotic disorders have
a greater sensitivity to the psychotogenic effect of cannabis66 and
if they develop a cannabis-induced psychotic disorder, they are
more likely to transition to schizophrenia.68 Furthermore,
individuals who have a high schizophrenia PRS and use cannabis
heavily are at higher risk for psychosis than those who either carry
a high schizophrenia PRS or smoke cannabis heavily.32 A recent
study described an additive interaction between schizophrenia
PRS and cannabis use,32,49 with no evidence that genetic liability
increases the risk for cannabis use.
Another potentially vulnerable population might be represented
by individuals exposed to childhood adversity, whichmay enhance
the psychotogenic effect of cannabis, through sensitization.
Several studies observed that the joined effect of early trauma
and cannabis use onpsychosiswas greater than their independent
effect,54,62,63,70 but the findings were not fully consistent.7,86,112
5. Cannabis and cognitive impairment
Two meta-analyses47,107 described a modest residual cannabis-
related impairment in measures of both overall and specific
cognitive functions after 12 hours to 25 days of abstinence, with
no residual cognitive impairment after 25 days of abstinence.107
Another meta-analysis including samples of adolescent and
young adults found a modest overall negative effect (d520.25;
95% CI 20.32 to 20.17) of cannabis use on cognition and no
residual effect (d 5 20.08; 95% CI 20.22 to 0.07).109
In young adults, chronic cannabis use most commonly affects
immediate recall and verbal reasoning12,38,118 but not spatial
working memory; however, the latter is affected in adolescents,55
suggestive of a differential effect on the developing brain. Both in
adolescents and adult users, attention is impaired during
cannabis intoxication and persists for several weeks.61 Executive
function domains (eg, inhibition, problem solving) are differently
affected by acute or chronic cannabis use, and it is not clear how
likely impairments are to persist after abstinence.27,75
6. Cannabis and bipolar disorder
Regular cannabis use is associated to about a 3-fold risk (OR 5
2.97, 95% CI 1.8-4.9) of developing a manic episode, with some
evidence of dose–response relationship between frequency of
use and risk for mania.42,81,94 Furthermore, continued cannabis
use and CUDs increases the severity of manic and psychotic
symptoms and facilitates a rapid-cycling course of bipolar
disorder.42,80
7. Cannabis, depression, and anxiety
Regular cannabis use is associated with lack of motivation for
naturally rewarding activities, which is a core feature of depressive
disorders.117 Systematic reviews indicate that cannabis use
leads to a modest increase in the risk for depression (OR5 1.49,
95%CI 1.15-1.94),85 which becomes slightly greater (OR5 1.62,
95% CI 1.21-2.16)78 for frequent cannabis use. Furthermore,
those who start using cannabis at age5,15 years are at greater
risk for suicidal ideation (OR 5 1.50, 95% CI 1.11-2.03) and
suicidal behaviours (OR 5 3.46, 95% CI 1.53-7.84) both in
general population and clinical samples.44
Evidence for a weaker association between cannabis use and
anxiety disorders comes from a meta-analysis, estimating ORs
from 1.15 (95% CI 1.03-1.29)113 to 1.24 (95% CI 1.06-1.45).67
Nevertheless, more longitudinal studies are needed to clarify the
direction of the association between cannabis use depression
and anxiety,78,113 to examine the role of self-medication.20,119
8. Conclusions
All prescribed and recreational drugs have adverse effects, even
those coming from plants, fruits, and flowers as we have learnt
from the use of tobacco, alcohol, and opium. Cannabis is not an
exception (Tables 1 and 2). Therefore, at a time of changes in the
laws concerning cannabis use, it is of clinical and public health
importance to provide evidence-based and clear information on
what we know concerning (1) the acute and persistent adverse
effects and (2) how to screen for those individuals more
susceptible to experience them when cannabis is used recrea-
tionally or medicinally.
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Llorca PM, Schürhoff F. Differential effects of childhood trauma and
cannabis use disorders in patients suffering from schizophrenia.
Schizophr Res 2016;175:161–7.
[8] Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R,
Borgwardt S, Winton-Brown T, Nosarti C, O’Carroll CM, Seal M, Allen
Copyright © 2020 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.
Month 2020·Volume 00·Number 00 www.painjournalonline.com 5
P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM,
Zuardi AW, Crippa JA, Atakan Z, McGuire PK. Opposite effects of d-9-
tetrahydrocannabinol and cannabidiol on human brain function and
psychopathology. Neuropsychopharmacology 2010;35:764–74.
[9] Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M,
Degenhardt L. Cannabinoids for the treatment of mental disorders and
symptoms of mental disorders: a systematic review and meta-analysis.
Lancet Psychiatry 2019;6:995–1010.
[10] Bonn-Miller MO, ElSohly MA, Loflin MJE, Chandra S, Vandrey R.
Cannabis and cannabinoid drug development: evaluating botanical
versus single molecule approaches. Int Rev Psychiatry 2018;30:
277–84.
[11] Boydell J, Van Os J, Caspi A, Kennedy N, Giouroukou P, Fearon P,
Farrell M, Murray RM. Trends in cannabis use prior to first presentation
with schizophrenia, in South-East London between 1965 and 1999.
Psychol Med 2006;36:1441–6.
[12] Broyd SJ, Van Hell HH, Beale C, Yücel M, Solowij N. Acute and chronic
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Peñas J, Pignon B, Rapado M, Richard JR, Rodrı́guez Solano JJ, Roldán
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Galea S, Pacula R, Feng T. Medical marijuana laws and adolescent
marijuana use in the USA from 1991 to 2014: results from annual,
repeated cross-sectional surveys. Lancet Psychiatry 2015;2:601–8.
[59] Hjorthøj C, Larsen MO, Starzer MSK, Nordentoft M. Annual incidence of
cannabis-induced psychosis, other substance-induced psychoses and
dually diagnosed schizophrenia and cannabis use disorder in Denmark
from 1994 to 2016. Psychol Med 2019. doi: 10.1017/
S0033291719003532 [Epub ahead of print].
[60] Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986;38:1–20.
[61] Hooper SR, Woolley D, De Bellis MD. Intellectual, neurocognitive, and
academic achievement in abstinent adolescents with cannabis use
disorder. Psychopharmacology (Berl) 2014;231:1467–77.
[62] Houston JE, Murphy J, Adamson G, Stringer M, Shevlin M. Childhood
sexual abuse, early cannabis use, and psychosis: testing an interaction
model based on the national comorbidity survey. Schizophr Bull 2008;
34:580–5.
[63] Houston JE, Murphy J, Shevlin M, Adamson G. Cannabis use and
psychosis: re-visiting the role of childhood trauma. Psychol Med 2011;
41:2339–48.
[64] Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA,
Moolchan ET, Frank RA, Dsouza DC, Kosten TR. Blockade of effects of
smoked marijuana by the CB1-selective cannabinoid receptor
antagonist SR141716. Arch Gen Psychiatry 2001;58:322–8.
[65] Jones RT. Marihuana: Human effects. In: Iversen LL, Iversen SD, Snyder
SH (eds) Handbook of Psychopharmacology. Drugs of Abuse. New
York, NY: Plenum Press, 1978. pp. 373–412.
[66] Kahn RS, Linszen DH, VanOs J,WiersmaD, Bruggeman R, CahnW, De
Haan L, Krabbendam L, Myin-Germeys I. Evidence that familial liability
for psychosis is expressed as differential sensitivity to cannabis: an
analysis of patient-sibling and sibling-control pairs. Arch Gen Psychiatry
2011;68:138–47.
[67] Kedzior KK, Laeber LT. A positive association between anxiety disorders
and cannabis use or cannabis use disorders in the general population-
a meta-analysis of 31 studies. BMC Psychiatry 2014;14:136.
[68] Kendler KS, Ohlsson H, Sundquist J, Sundquist K. Prediction of onset of
substance-induced psychotic disorder and its progression to
schizophrenia in a Swedish national sample. Am J Psychiatry 2019;
176:711–19.
[69] Kolliakou A, Joseph C, Ismail K, Atakan Z, Murray RM. Why do patients
with psychosis use cannabis and are they ready to change their use ? Int
J Dev Neurosci 2011;29:335–46.
[70] Konings M, Stefanis N, Kuepper R, de Graaf R, Have MT, van Os J,
Bakoula C, Henquet C. Replication in two independent population-
based samples that childhood maltreatment and cannabis use
synergistically impact on psychosis risk. Psychol Med 2011;42:
149–59.
[71] Kosiba JD, Maisto SA, Ditre JW. Patient-reported use of medical
cannabis for pain, anxiety, and depression symptoms: systematic
review and meta-analysis. Soc Sci Med 2019;233:181–92.
[72] Kraan T, Velthorst E, Koenders L, Zwaart K, Ising HK, Van Den Berg D,
DeHaan L, VanDer GaagM.Cannabis use and transition to psychosis in
individuals at ultra-high risk: review and meta-analysis. Psychol Med
2016;46:673–81.
[73] Kuepper R, Morrison PD, van Os J, Murray RM, Kenis G, Henquet C.
Does dopamine mediate the psychosis-inducing effects of cannabis? A
review and integration of findings across disciplines. Schizophr Res
2010;121:107–17.
[74] Lafaye G, Karila L, Blecha L, Benyamina A. Cannabis, cannabinoids,
and health. Dialogues Clin Neurosci 2017;19:309–16.
[75] Lane SD, Cherek DR, Tcheremissine OV, Steinberg JL, Sharon JL.
Response perseveration and adaptation in heavy marijuana-smoking
adolescents. Addict Behav 2007;32:977–90.
[76] Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM. Cannabidiol
is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J
Pharmacol 2015;172:4790–805.
[77] Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use
and earlier onset of psychosis: a systematic meta-analysis. Arch Gen
Psychiatry 2011;68:555–61.
[78] Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J.
The association between cannabis use and depression: a systematic
review and meta-analysis of longitudinal studies. Psychol Med 2014;44:
797–810.
[79] Lichtman AH, Martin BR. Cannabinoid tolerance and dependence
Cannabinoids. In: Pertwee RG (ed). Handbook of Experimental
Pharmacology. Heidelberg: Springer-Verlag. 2005;168:691–717.
[80] Mammen G, Rueda S, Roerecke M, Bonato S, Lev-Ran S, Rehm J.
Association of cannabis with long-term clinical symptoms in anxiety and
mood disorders: a systematic review of prospective studies. J Clin
Psychiatry 2018;79:17r11839.
[81] Marangoni C, Hernandez M, Faedda GL. The role of environmental
exposures as risk factors for bipolar disorder: a systematic review of
longitudinal studies. J Affect Disord 2016;193:165–74.
[82] Marconi A, Di Forti M, Lewis CM,Murray RM, Vassos E.Meta-Analysis of
the association between the level of cannabis use and risk of psychosis.
Schizophr Bull 2016;42:1262–9.
[83] Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure
of a cannabinoid receptor and functional expression of the cloned
cDNA. Nature 1990;346:561–4.
[84] Mechoulam R. Plant cannabinoids: a neglected pharmacological
treasure trove. Br J Pharmacol 2005;146:913–15.
[85] Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke
M, Lewis G. Cannabis use and risk of psychotic or affective mental
health outcomes: a systematic review. Lancet 2007;370:319–28.
[86] Morgan C, Reininghaus U, Reichenberg A, Frissa S, Hotopf M, Hatch
SL. Adversity, cannabis use and psychotic experiences: evidence of
cumulative and synergistic effects. Br J Psychiatry 2014;204:346–53.
[87] Morgan CJA, Curran HV. Effects of cannabidiol on schizophrenia-like
symptoms in people who use cannabis. Br J Psychiatry 2008;192:306–7.
Copyright © 2020 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.
Month 2020·Volume 00·Number 00 www.painjournalonline.com 7
[88] Murray RM, Englund A, Abi-Dargham A, Lewis DA, Di Forti M, Davies C,
Sherif M, McGuire P, D’Souza DC. Cannabis-associated psychosis: neural
substrate and clinical impact. Neuropharmacology 2017;124:89–104.
[89] Murray RM, Quigley H, Quattrone D, Englund A, Di Forti M. Traditional
marijuana, high-potency cannabis and synthetic cannabinoids:
increasing risk for psychosis. World Psychiatry 2016;15:195–204.
[90] Niesink RJM, Rigter S. THC-concentraties in wiet, nederwiet en hasj in
Nederlandse coffeeshops (2012–2013). Utrecht, The Netherlands:
Trimbos-instituut, 2013.
[91] Notcutt W, Price M,Miller R, Newport S, Phillips C, Simmons S, Sansom
C. Initial experiences with medicinal extracts of cannabis for chronic
pain: results from 34 “N of 1” studies. Anaesthesia 2004;59:440–52.
[92] Van Os J, Bak M, Hanssen M, Bijl RV, De Graaf R, Verdoux H. Cannabis
use and psychosis: a longitudinal population-based study. Am J
Epidemiol 2002;156:319–27.
[93] Pasman JA, Verweij KJH, Gerring Z, Stringer S, Sanchez-Roige S, Treur
JL, Abdellaoui A, Nivard MG, Baselmans BML, Ong JS, Ip HF, van der
Zee MD, Bartels M, Day FR, Fontanillas P, Elson SL, de Wit H, Davis LK,
MacKillop J, Derringer JL, Branje SJT, Hartman CA, Heath AC, van Lier
PAC, Madden PAF, Mägi R, MeeusW,Montgomery GW, Oldehinkel AJ,
Pausova Z, Ramos-Quiroga JA, Paus T, Ribases M, Kaprio J, Boks
MPM, Bell JT, Spector TD, Gelernter J, Boomsma DI, Martin NG,
MacGregor S, Perry JRB, Palmer AA, Posthuma D, Munafò MR,
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